---
title: "Sinopharm Accord, Sinopharm Group subsidiary, posts H1 net profit RMB 606 million, down 8.97%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296110219.md"
description: "Sinopharm Accord, a subsidiary of Sinopharm Group, reported preliminary unaudited H1 2026 results showing an 8.97% decline in net profit to RMB 606.2 million. Revenue fell 1.44% to RMB 36.27 billion, while operating profit dropped 9.94% to RMB 834.43 million. Total assets decreased slightly by 1.89%, whereas equity attributable to shareholders rose 1.42%. Basic EPS slipped to RMB 0.99."
datetime: "2026-08-17T12:57:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296110219.md)
  - [en](https://longbridge.com/en/news/296110219.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296110219.md)
generator: "portal-rs"
---

# Sinopharm Accord, Sinopharm Group subsidiary, posts H1 net profit RMB 606 million, down 8.97%

-   Sinopharm Accord, a subsidiary of Sinopharm Group, released preliminary unaudited results for the six months ended June 30, 2026. \* Revenue fell 1.44% to RMB 36.27 billion; operating profit dropped 9.94% to RMB 834.43 million. \* Net profit attributable to shareholders declined 8.97% to RMB 606.2 million; basic EPS slipped to RMB 0.99. \* Total assets edged down 1.89% to RMB 48.17 billion; equity attributable to shareholders rose 1.42% to RMB 18.87 billion. \* Distribution revenue decreased 0.91% to RMB 26.54 billion; retail revenue fell 2.4% to RMB 10.23 billion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260817-12287437), on August 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [000028.CN](https://longbridge.com/en/quote/000028.CN.md)
- [200028.CN](https://longbridge.com/en/quote/200028.CN.md)
- [01099.HK](https://longbridge.com/en/quote/01099.HK.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [Sinopharm Accord Posts Steady Nine-Month Results but Strong Q3 Profit Rebound](https://longbridge.com/en/news/302436104.md)
- [Sinopharm Accord, Sinopharm Group unit, posts H1 net profit attributable to shareholders down 8.97% to RMB 606.2 million](https://longbridge.com/en/news/297300414.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**